BioLargo, Inc. has announced that it has entered into a purchase agreement with Clearthink Capital Partners, LLC, allowing Clearthink to purchase up to $10 million of the company's common stock. This agreement, dated March 20, 2026, includes a registration rights agreement that will enable Clearthink to resell the shares acquired under the agreement. The company has the discretion to sell shares to Clearthink over a 36-month period, subject to certain conditions, including the effectiveness of a registration statement with the SEC. The purchase price for the shares will be based on the average of the two lowest daily closing prices of BioLargo's common stock during the eight trading days preceding the purchase notice. The agreement also includes a commitment fee of 500,000 shares of common stock to be issued to Clearthink upon execution of the agreement. BioLargo expects to use the proceeds from this agreement for working capital and general corporate purposes. This financing arrangement is expected to enhance the company's liquidity position and provide necessary capital for its operations.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.